References
- Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 2013;368:1613-24
- Janssen Pharmaceuticals Inc. Prescribing Information: Invokana. Titusville, NJ, USA: Janssen Pharmaceuticals Inc., March 2015
- Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
- Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes: a randomized trial. Hosp Pract (1995) 2013;41:72-84
- Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
- Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014;16:467-77
- Lavalle-González F, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92
- Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care 2013;36:2508-15
- Godinho R, Mega C, Teixeira-de-Lemos E, et al. The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a ‘me too’ or ‘the special one’ antidiabetic class? J Diabetes Res. 2015;2015:806979
- Grabner M, Peng X, Germakis C, Bae J. Demographic and clinical profiles of type 2 diabetes mellitus patients initiating canagliflozin versus DPP-4 inhibitors in a large U.S. managed care population. J Manag Care Spect Pharm 2015;21:1204-12
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
- Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-23
- Chang HY, Weiner JP, Richards TM, et al. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care 2012;18:721-6
- Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2001;2:169-88
- Bailey RA, Damaraju CV, Martin SC, et al. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. Am J Manag Care 2014;20:S16-24
- Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trial. Diab Vasc Dis Res 2015;12:90-100
- Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complication of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
- De Berardis G, Pellegrini F, Franciosi M, et al. Quality of diabetes care predicts the development of cardiovascular events: results of the QuED study. Nutr Metab Cardiovasc Dis 2008;18:57-65
- Ektare, VU, Lopez JMS, Martin SC, et al. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus. Am J Manag Care 2014;20(Suppl 10):S204-15
- Buysman EK, Chow W, Henk HJ, et al. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. BMC Endocr Disord 2015;15:67
- Xie L, Zhou S, Pinsky BW, et al. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. Diabetes Technol Ther 2014;16:567-75